owned by nations where seaweed production is traditionally important, but that also invest significantly in research (e.g., China and Japan). The remaining patent registrations are distributed among nations that produce little or no seaweed but support a large output of seaweed research (e.g., US and France). In contrast, top-ranking seaweed producers with little invested in research do not participate in the patent market (e.g., The Philippines, Indonesia and Vietnam).
Indeed, differences in production and research effort explained 50% of the variability in the number of patents among nations (F = 20.5, P < 0.0001), with research effort emerging as the main driver of differences in the number of patents (accounting for 96% of the variance explained, F = 41.9, P < 0.0001). Among countries that invested substantially in research (those with more than 20 peerreviewed publications on seaweed published in the period 1980-2009), the number of patent registrations increased where seaweed production was higher (e.g., Japan and China), whereas in countries where the research effort was minimal (e.g., Indonesia and Vietnam), the number of patents appeared unrelated to the rate of production. This implies that seaweed aquaculture leads to innovation only when accompanied by substantial scientific effort. Our analysis highlights the importance of research effort in driving innovation and reveals an important return in intellectual property from investments in seaweed biotechnology research.
These results identify an opportunity to reverse the current weak participation of developing countries in the seaweed patent market by strengthening cooperation to transfer technological knowledge and investment to developing nations active in seaweed aquaculture, thereby promoting sustainable development based on their own natural resources, as encouraged by the Convention on Biological Diversity 11 .
In the absence of such cooperative efforts, the emergence of new, more sophisticated biotechnology applications for seaweed products (e.g., cosmetics, bioenergy and biomedicine) may continue to widen the division between developed countries focused on high-value applications and developing countries focused on the mass production of seaweed, where the lack of research investment clearly precludes their participation in the seaweed patent market. 
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To the Editor:
In their paper "Performance comparison of benchtop high-throughput sequencing platforms" published in the May 2012 issue, Loman et al. 1 provide a detailed comparison of the metrics associated with three different benchtop DNA sequencing platforms for the assembly of a single genome. Information was given on read-level metrics, such as length, accuracy and alignment, and on assembly-level metrics, such as contig N50 and gap number. The results were discussed in the context of the utility of whole-genome sequencing for public health microbiology. We believe, however, that one of the primary uses for sequencing in clinical microbiology (at least initially) will be in the detection of pathogen transmission
Read and assembly metrics inconsequential for clinical utility of whole-genome sequencing in mapping outbreaks 4 .
In brief, an outbreak investigation was initiated when the infection control team at the Cambridge University Hospitals National Health Service Foundation Trust noted that three infants on the Special Care Baby Unit were MRSA-positive on screening swabs. A retrospective look-back over six months identified a total of 17 MRSApositive patients in three distinct clusters. We extracted and sequenced DNA from 24 MRSA isolates-15 from patients suspected to be involved in the outbreak (corresponding to P1 to P15 in Fig. 1a ,b of the original paper) 4 and nine from control patients elsewhere in the hospital. The isolates were sequenced on HiSeq, MiSeq and Ion Torrent platforms with read-lengths of 76, 150 and ~150 bp, to an average coverage of 204.81-, 77.74-and 71.98-fold, respectively (Box 1). We used a simple processing pipeline for each data set, using the read-mapping and SNP-calling parameters described in Box 1.
All three platforms clearly discriminated outbreak from nonoutbreak MRSA strains (with an average of 13,154 SNP differences between outbreak and nonoutbreak isolates called by MiSeq and 13,297 differences called by the PGM). All platforms also clearly discriminated among the near-identical outbreak strains, identifying a total of 23 SNPs among the 15 strains. The initial MiSeq data called one extra SNP in one outbreak strain, which was subsequently identified as a readmapping error. However, this did not affect the identified relationships among the strains. In every case, the HiSeq and MiSeq results were identical. The larger number of SNPs seen in the Ion Torrent data for the outbreak to nonoutbreak comparison supports previous data showing that Ion Torrent had a higher false-positive SNP rate when comparing more distantly related organisms 8 .
In conclusion, we found that despite the different read metrics and error profiles identified previously, both rapid-turnaround platforms (MiSeq and Ion Torrent) produced similar clinically actionable data when applied to a real-world outbreak, both in terms of discriminating outbreak from nonoutbreak strains and in identifying the small number of discriminatory SNPs within the outbreak. The error profiles of individual reads and the differences in quality of assembly do not have any effect on the utility of the output when sufficient read-coverage is obtained in mapping-based approaches. Decisions on which platform to use for clinical microbiology should therefore be based on other considerations, such as easeof-use, complete pipeline turnaround time (including DNA and library preparation, not just machine run time) 9 , and per-base and per-run costs. Although this comparison has concentrated on read-mapping and SNP calling in outbreak situations, small indels can contain useful phylogenetic information, and genomes assembled de novo clearly have other uses in clinical microbiology, including generation of accurate reference sequences and identification of novel genes in outbreak strains. For these uses, the performance of the different platforms does vary, and comparative analyses such as that produced by Loman et al. 1 should be taken into account when choosing an appropriate platform.
Note: Supplementary information is available in the online version of the paper (doi:10.1038/nbt.2616).
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Box 1 Methods
Reads were mapped against the chromosome of an EMRSA-15 reference, HO 50960412 (accession number HE681097), using SMALT version 0.6.4 (http://www.sanger.ac.uk/ resources/software/smalt/). Reads that aligned equally well to two or more locations in the reference sequence were not mapped. For HiSeq and MiSeq data, paired reads were mapped with an expected insert size of between 50 and 1,000 bp, whereas Ion Torrent data reads were mapped as single ended. In all cases, reads containing indels were realigned using the Genome Analysis Toolkit 10 RealignerTargetCreator and IndelRealigner modules. Variants were called using a combination of samtools 11 mpileup and bcftools. For HiSeq and MiSeq data, default options were used, whereas for Ion Torrent data, settings were chosen as used in the Ion Torrent Variant Caller Plugin: for samtools mpileup, a minimum base quality of 7 was used instead of the default of 13, the coefficient of homopolymer errors was reduced to 50 from the default of 100, the minimum number of reads required for an indel candidate was increased to 4 from a default of 1 and the phred-scaled gap opening and extension probabilities were reduced to 10 and 17 from the defaults of 40 and 20, respectively. Pseudosequences for each isolate were then created by filtering all bases using the following filters: (i) base must be covered by at least four reads, of which at least two must be on each strand; and (ii) bases must have a quality score >50 and a mapping quality >30, and the majority base must be present in at least 75% of reads on each strand. Phylogenetic trees of variable sites were reconstructed with RAxML 12 , and SNPs reconstructed onto the trees using parsimony. Raw reads for each platform are available from the European Nucleotide Archive under project accession number ERP000985. Accessions for individual samples are shown in Supplementary Table 1.
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